0.97
+0.0124(+1.29%)
Currency In USD
| Previous Close | 0.96 |
| Open | 1 |
| Day High | 1 |
| Day Low | 0.95 |
| 52-Week High | 1.59 |
| 52-Week Low | 0.77 |
| Volume | 245,259 |
| Average Volume | 562,911 |
| Market Cap | 84.97M |
| PE | -3.35 |
| EPS | -0.29 |
| Moving Average 50 Days | 1.02 |
| Moving Average 200 Days | 1.13 |
| Change | 0.01 |
If you invested $1000 in Cardiol Therapeutics Inc. (CRDL) since IPO date, it would be worth $259.89 as of January 14, 2026 at a share price of $0.972. Whereas If you bought $1000 worth of Cardiol Therapeutics Inc. (CRDL) shares 5 years ago, it would be worth $358.82 as of January 14, 2026 at a share price of $0.972.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Newsfile
Yesterday at 12:27 PM GMT
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment m
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Newsfile
Dec 01, 2025 12:27 PM GMT
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidenc
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Newsfile
Nov 13, 2025 12:45 PM GMT
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceuti